Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuko Tajiri

Showing results (1-10 of 97) with videos related to

Pageof 10
Sort By:
Internal Medicine (Tokyo, Japan)|October 20, 2024
Addressing Cardiotoxicity Risks in Long-term Use of Human Epidermal Growth Factor Receptor 2 InhibitorsKazuko Tajiri
Internal Medicine (Tokyo, Japan)|April 24, 2024
Immune Checkpoint Inhibitor Myotoxicities: An Autoimmune PerspectiveKazuko Tajiri
The Canadian Journal of Cardiology|April 25, 2026
Toward Better Cardiovascular Risk Prediction in Cancer SurvivorsKazuko Tajiri
Japanese Journal of Clinical Oncology|March 29, 2022
Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patientsKazuko Tajiri, Ikuo Sekine
Frontiers in Cardiovascular Medicine|February 8, 2019
Cardiac Complications in Immune Checkpoint Inhibition TherapyKazuko Tajiri, Masaki Ieda
Internal Medicine (Tokyo, Japan)|January 15, 2023
Neoplastic Cardiac TamponadeTakumi Osawa, Kazuko Tajiri
Internal Medicine (Tokyo, Japan)|September 23, 2020
A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor TherapySiqi Li, Kazuko Tajiri
Internal Medicine (Tokyo, Japan)|March 14, 2022
A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor TherapyYoshiko Murakata, Kazuko Tajiri
Internal Medicine (Tokyo, Japan)|November 19, 2023
The Need for Next-generation Anticoagulation Therapies for Cancer-associated Venous ThromboembolismYuki Ishizuka, Kazuko Tajiri
Internal Medicine (Tokyo, Japan)|April 4, 2022
Galectin-3 as an Arrhythmogenic Predictive Marker for Heart FailureKeiko Inoue, Kazuko Tajiri
Pageof 10

Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
Internal Medicine (Tokyo, Japan)|October 20, 2024
Addressing Cardiotoxicity Risks in Long-term Use of Human Epidermal Growth Factor Receptor 2 InhibitorsKazuko Tajiri
Internal Medicine (Tokyo, Japan)|April 24, 2024
Immune Checkpoint Inhibitor Myotoxicities: An Autoimmune PerspectiveKazuko Tajiri
The Canadian Journal of Cardiology|April 25, 2026
Toward Better Cardiovascular Risk Prediction in Cancer SurvivorsKazuko Tajiri
Japanese Journal of Clinical Oncology|March 29, 2022
Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patientsKazuko Tajiri, Ikuo Sekine
Frontiers in Cardiovascular Medicine|February 8, 2019
Cardiac Complications in Immune Checkpoint Inhibition TherapyKazuko Tajiri, Masaki Ieda
Internal Medicine (Tokyo, Japan)|January 15, 2023
Neoplastic Cardiac TamponadeTakumi Osawa, Kazuko Tajiri
Internal Medicine (Tokyo, Japan)|September 23, 2020
A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor TherapySiqi Li, Kazuko Tajiri
Internal Medicine (Tokyo, Japan)|March 14, 2022
A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor TherapyYoshiko Murakata, Kazuko Tajiri
Internal Medicine (Tokyo, Japan)|November 19, 2023
The Need for Next-generation Anticoagulation Therapies for Cancer-associated Venous ThromboembolismYuki Ishizuka, Kazuko Tajiri
Internal Medicine (Tokyo, Japan)|April 4, 2022
Galectin-3 as an Arrhythmogenic Predictive Marker for Heart FailureKeiko Inoue, Kazuko Tajiri
Pageof 10